Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three ways to trigger ovulation: which yields more mature eggs in Low-Reserve IVF?

NCT ID NCT07816562

Disease control Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers compare three ovulation trigger approaches in women with low ovarian reserve undergoing fresh IVF cycles. Participants receive either human chorionic gonadotropin (hCG) alone, follitropin delta plus hCG, or a dual trigger using a GnRH agonist plus hCG. The trial measures how many mature eggs are retrieved and tracks pregnancy outcomes after fresh embryo transfer. The goal is to find out whether adding follitropin delta at trigger time increases mature egg yield without hurting implantation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ovulation trigger medications: human chorionic gonadotropin (hCG), follitropin delta, and triptorelin
What this could lead to
If one trigger approach works better, it could help women with low ovarian reserve retrieve more mature eggs during IVF and improve their chances of pregnancy.
What could go wrong
This is a single Phase 3 trial with 126 participants, so results may not apply to all women with low ovarian reserve. Adding follitropin delta could fail to increase mature eggs or might affect implantation, and pregnancy outcomes remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 42 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent. * Women aged between 18 and 42 years. * Primary infertility. * Women with low ovarian response classified within one of the groups defined by the POSEIDON criteria. Exclusion Criteria: * More than two previous failed ovarian stimulation cycles. * Female age \>42 years. * Body mass index (BMI) \>35 kg/m². * Criteria of extremely low ovarian reserve according to the Spanish National Health System exclusion criteria (AMH \<0.3 ng/mL and/or antral follicle count \<5). * Male partner age \>55 years. * Severe male factor infertility (total motile sperm count \<1 million). * Previous voluntary sterilization (vasectomy or bilateral tubal ligation). * Previous healthy child shared by the couple. * Presence of medical conditions contraindicating pregnancy. * Risk of ovarian hyperstimulation syndrome (OHSS). If more than 15 follicles are expected on the day of trigger, the patient will be excluded from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low ovarian reserve are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Low ovarian reserve Poor ovarian response

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.